- Home
- FSV vs JAZZ Comparison
FSV vs JAZZ Comparison
Compare FSV & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSV
- JAZZ
- Stock Information
- Founded
- FSV 1988
- JAZZ 2003
- Country
- FSV Canada
- JAZZ Ireland
- Employees
- FSV N/A
- JAZZ N/A
- Industry
- FSV Real Estate
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- FSV Finance
- JAZZ Health Care
- Exchange
- FSV Nasdaq
- JAZZ Nasdaq
- Market Cap
- FSV 8.0B
- JAZZ 6.7B
- IPO Year
- FSV N/A
- JAZZ 2007
- Fundamental
- Price
- FSV $175.69
- JAZZ $108.80
- Analyst Decision
- FSV Buy
- JAZZ Strong Buy
- Analyst Count
- FSV 4
- JAZZ 12
- Target Price
- FSV $204.75
- JAZZ $183.08
- AVG Volume (30 Days)
- FSV 128.0K
- JAZZ 662.9K
- Earning Date
- FSV 07-24-2025
- JAZZ 07-30-2025
- Dividend Yield
- FSV 0.60%
- JAZZ N/A
- EPS Growth
- FSV 42.94
- JAZZ 49.21
- EPS
- FSV 2.88
- JAZZ 7.51
- Revenue
- FSV $5,309,675,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- FSV $7.67
- JAZZ $6.05
- Revenue Next Year
- FSV $6.82
- JAZZ $4.68
- P/E Ratio
- FSV $60.61
- JAZZ $14.57
- Revenue Growth
- FSV 18.68
- JAZZ 5.76
- 52 Week Low
- FSV $150.53
- JAZZ $95.49
- 52 Week High
- FSV $197.84
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- FSV 51.25
- JAZZ 44.79
- Support Level
- FSV $171.63
- JAZZ $105.57
- Resistance Level
- FSV $179.42
- JAZZ $109.21
- Average True Range (ATR)
- FSV 3.36
- JAZZ 2.45
- MACD
- FSV -0.37
- JAZZ -0.22
- Stochastic Oscillator
- FSV 43.16
- JAZZ 18.01
About FSV FirstService Corporation
FirstService Corp operates in two business divisions: FirstService Residential and FirstService Brands. FirstService Residential has service contracts to manage thousands of residential communities, including high-, medium-, and low-rise condominiums and co-operatives. FirstService Brands generates the majority of the company's revenue and provides property services to residential and commercial customers through the following brands: California Closets; Paul Davis Restoration; CertPro Painters; Pillar to Post; Floor Coverings International; College Pro Painters; and Service America. The company earns the majority of its revenue in the United States, with the remaining revenue generated in Canada.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.